Delayed treatment with nerve growth factor (NGF) reverses ECMA-induced cholinergic lesions in rat brain reaggregate cultures.
Atterwill
C K
CK
Smith Kline & French Research Ltd, Welwyn, Herts, U.K.
Meakin
J M
JM
D000818:Animals; D001388:Aziridines / Q000037:antagonists & inhibitors* / Q000633:toxicity; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D002478:Cells, Cultured; D002794:Choline / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000633:toxicity; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D009414:Nerve Growth Factors / Q000494:pharmacology*; D009466:Neuromuscular Blocking Agents / Q000037:antagonists & inhibitors*; D051381:Rats
D001388:Aziridines; D009414:Nerve Growth Factors; D009466:Neuromuscular Blocking Agents; C044894:ethylcholine aziridinium; D002795:Choline O-Acetyltransferase; D002794:Choline